The use of medicinal cannabis in the treatment of opioid use disorders: A systematic review
DOI:
https://doi.org/10.33448/rsd-v12i9.43224Keywords:
Opiate Substitution Treatement; Opioid-Related Disorders; Canabinoids; Cannabis.Abstract
The search for alternative treatments and different clinical uses of medicinal cannabis has shown significant growth in recent years. In this context, this study aims to evaluate the use of medicinal cannabis as a treatment for opioid use disorders. Through a systematic analysis, using the PubMed and Medline databases, a search was carried out, giving preference to clinical trials, meta-analyses and bibliographic reviews from the last 10 years, in animals and humans using the terms “cannabis”, “opioids”, “addiction” and “treatment”. Articles with the terms “smoker”, “smoking” and “pregnant” in the title or abstract were excluded, and ongoing studies were also excluded. A reduction in withdrawal symptoms was observed, with a prolonged effect and a good safety profile. Studies show positive preliminary results, however, they have small samples, without standardization of synthetic cannabinoids and their respective dosages. Therefore, studies with standardization of parameters and a larger sample number are necessary for assertive conclusions.
References
Balu, A., Mishra, D., Marcu, J., & Balu, G. (2021). Medical cannabis certification is associated with decreased opiate use in patients with chronic pain: A Retrospective cohort study in delaware. Cureus. https://doi.org/10.7759/cureus.20240
Boehnke, K. F., Litinas, E., & Clauw, D. J. (2016). Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. The Journal of Pain, 17(6), 739–744. https://doi.org/10.1016/j.jpain.2016.03.002
Campbell, G., Hall, W., & Nielsen, S. (2018). What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review. International Review of Psychiatry, 30(5), 91–106. https://doi.org/10.1080/09540261.2018.1509842
Capano, A., Weaver, R., & Burkman, E. (2019). Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgraduate Medicine, 132(1), 56–61. https://doi.org/10.1080/00325481.2019.1685298
Degenhardt, L., Charlson, F., Stanaway, J., Larney, S., Alexander, L. T., Hickman, M., Cowie, B., Hall, W. D., Strang, J., Whiteford, H., & Vos, T. (2016). Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. The Lancet Infectious Diseases, 16(12), 1385–1398. https://doi.org/10.1016/s1473-3099(16)30325-5
Degenhardt, L., Peacock, A., Colledge, S., Leung, J., Grebely, J., Vickerman, P., Stone, J., Cunningham, E. B., Trickey, A., Dumchev, K., Lynskey, M., Griffiths, P., Mattick, R. P., Hickman, M., & Larney, S. (2017). Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet. Global Health, 5(12), e1192–e1207. https://doi.org/10.1016/S2214-109X(17)30375-3
Estrela, C. (2018). Metodologia científica ciência, ensino, pesquisa. Artes Medicas.
Hurd, Y. L., Spriggs, S., Alishayev, J., Winkel, G., Gurgov, K., Kudrich, C., Oprescu, A. M., & Salsitz, E. (2019). Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. American Journal of Psychiatry, 176(11), 911–922. https://doi.org/10.1176/appi.ajp.2019.18101191
Kathmann, M., Flau, K., Redmer, A., Tränkle, C., & Schlicker, E. (2006). Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn-Schmiedeberg’s Archives of Pharmacology, 372(5), 354–361. https://doi.org/10.1007/s00210-006-0033-x
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan-Wright, E. M. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology, 172(20), 4790–4805. https://doi.org/10.1111/bph.13250
Lucas, P. (2012). Cannabis as an Adjunct to or Substitute for Opiates in the Treatment of Chronic Pain. Journal of Psychoactive Drugs, 44(2), 125–133. https://doi.org/10.1080/02791072.2012.684624
Lucas, P., & Walsh, Z. (2017). Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. International Journal of Drug Policy, 42, 30–35. https://doi.org/10.1016/j.drugpo.2017.01.011
McKee, K. A., Hmidan, A., Crocker, C. E., Lam, R. W., Meyer, J. H., Crockford, D., Trépanier, A., Aitchison, K. J., & Tibbo, P. G. (2021). Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials. Journal of Psychiatric Research, 140, 267–281. https://doi.org/10.1016/j.jpsychires.2021.05.044
Mechoulam, R., Peters, M., Murillo-Rodriguez, E., & Hanuš, Lumír O. (2007). Cannabidiol – Recent Advances. Chemistry & Biodiversity, 4(8), 1678–1692. https://doi.org/10.1002/cbdv.200790147
Meng, H., Page, M. G., Ajrawat, P., Deshpande, A., Samman, B., Dominicis, M., Ladha, K. S., Fiorellino, J., Huang, A., Kotteeswaran, Y., McClaren-Blades, A., Kotra, L. P., & Clarke, H. (2021). Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in chronic pain patients. Canadian Journal of Anesthesia/Journal Canadien D’anesthésie, 68(5), 633–644. https://doi.org/10.1007/s12630-020-01903-1
Morales, P., Hurst, D. P., & Reggio, P. H. (2017). Molecular targets of the phytocannabinoids: A complex picture. Progress in the Chemistry of Organic Natural Products, 103, 103–131. https://doi.org/10.1007/978-3-319-45541-9_4
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007). Development of a Rational Scale to Assess the Harm of Drugs of Potential Misuse. Lancet (London, England), 369(9566), 1047–1053. https://doi.org/10.1016/S0140-6736(07)60464-4
Prud’homme, M., Cata, R., & Jutras-Aswad, D. (2015). Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence. Substance Abuse: Research and Treatment, 9, SART.S25081. https://doi.org/10.4137/sart.s25081
Razdan, R. K., Dalzell, H. C., Herlihy, P., & Howes, J. F. (1976). Hashish. 16. Unsaturated side-chain analogs of DELTA.8-tetrahydrocannabinol with potent biological activity. Journal of Medicinal Chemistry, 19(11), 1328–1330. https://doi.org/10.1021/jm00233a014
Russo, E. B., & Marcu, J. (2017). Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Cannabinoid Pharmacology, 80, 67–134. https://doi.org/10.1016/bs.apha.2017.03.004
Slivicki, R. A., Iyer, V., Mali, S. S., Garai, S., Thakur, G. A., Crystal, J. D., & Hohmann, A. G. (2020). Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. Frontiers in Molecular Neuroscience, 13. https://doi.org/10.3389/fnmol.2020.00054
Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020). Opioid use disorder. Nature Reviews Disease Primers, 6(1), 1–28. https://doi.org/10.1038/s41572-019-0137-5
Thakur, G., Nikas, S., & Makriyannis, A. (2005). CB1 Cannabinoid Receptor Ligands. Mini-Reviews in Medicinal Chemistry, 5(7), 631–640. https://doi.org/10.2174/1389557054368772
Vázquez, M., Guevara, N., Maldonado, C., Guido, P. C., & Schaiquevich, P. (2020). Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain. BioMed Research International, 2020, 1–9. https://doi.org/10.1155/2020/3902740
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Augusto Mendes Ferreira; Jullyana Sarah Magalhães Silva; Kaio Figueiredo da Silva Cruz; Marycassiely Rodrigues Tizolim; Washington Luiz Aquino de Souza Junior; Gabrielle Mendes Lima
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
